BioSpace News Archive

EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company”) announces that it has settled $1,378,241 of debt with creditors by issuing 4,139,161 common shares of the Company at deemed prices of $0.275, $0.30, $0.32, and $0.35 per share.

Hercules Pharmaceuticals, a Dutch biopharmaceutical company focusing on developing small molecule inhibitors of the Aryl Hydrocarbon Receptor (AhR) for treatment of cancer and viral infections, today announced the publication of promising preclinical in-vivo trial results,

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced the closing of its previously announced underwritten public offering of 3,333,334 shares of its common stock at a price to the public of $3.60 per share.

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced that it will hold a conference call on Monday, August 24, 2020 at 8:30 a.m. ET

Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological disorders who have unmet medical needs, today announced it has closed its upsized initial public offering of 6,151,162 shares of common stock,

Inhibrx, Inc. (“Inhibrx”) (Nasdaq: INBX), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, today announced the closing of its previously announced initial public offering of 8,050,000 shares of common stock,

PTC Therapeutics, Inc. announced that on August 18, 2020 it approved non-statutory stock options to purchase an aggregate of 49,165 shares of its common stock and 14,175 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to five new employees.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, will be releasing its Fiscal 2020 Third Quarter financial results on Monday August 24th, 2020, before markets open.

Brain stimulation therapy is a procedure to treat certain mental disorders.

Nanotechnology drug delivery is a growing field and is witnessing increasing acceptance in health care applications.